We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current VPHIF market cap is 4.63M. The company's latest EPS is CAD -0.2818 and P/E is -0.14.
| Year End October 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 6.83M | 7.47M | 13.56M | 27.75M | 53.91M |
| Operating Income | -3.48M | -4.34M | -12.45M | -19M | -17.39M |
| Net Income | -3.62M | -4.76M | -14.23M | -25.75M | -27.81M |
| Year End October 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 5.81M | 10.96M | 21.03M | 58.27M | 41.21M |
| Total Liabilities | 5.83M | 7.89M | 18.98M | 76.11M | 81.54M |
| Total Equity | -22k | 3.07M | 2.05M | -17.85M | -40.34M |
| Year End October 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | -2.31M | -5.3M | -12.32M | -28.5M | -15.7M |
| Investing | -923k | -1.41M | -3.47M | -6.89M | -5.55M |
| Financing | 3.55M | 9.21M | 15.1M | 54.99M | 6.19M |
| Market Cap | 4.63M |
| Price to Earnings Ratio | -0.14 |
| Price to Sales Ratio | 0.07 |
| Price to Cash Ratio | 0.53 |
| Price to Book Ratio | -0.1 |
| Dividend Yield | - |
| Shares Outstanding | 98.68M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -57.36% |
| 52 Week High | 0.254 |
| 52 Week Low | 0.03432 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Valeo Pharma Inc (CE) |
| Address |
16667 hymus blvd kirkland, washington H9H 4R9 |
| Website | https://www.valeopharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
